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CORRESPONDENCE
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We read with interest the article “EML4-ALK Fusion Gene in Ko-
rean Non-Small Cell Lung Cancer” in a recent issue of the Journal 
of Korean Medical Science by Jin et al. (1). In this study, EML4-
ALK fusion gene was detected in 10 of 167 non-small cell lung 
cancer (NSCLC) patients by using reverse transcriptase-poly-
merase chain reaction (RT-PCR) as a basic screening technique 
instead of fluorescence in situ hybridization (FISH) method. The 
frequency of EML4-ALK fusion gene in this study (6.0%) was 
not largely different from a previous study that used the FISH 
method on Korean NSCLC patients (4.2%) (2), while it did not 
diverge from the results in previous studies on a general NSCLC 
patient population that yielded 3%-7% ratios as well. Based on 
the experience of detecting leukemia fusion genes with several 
new molecular methods during the diagnosis of leukemia (3-6), 
we would like to mention the pros and cons of such methods in 
the analysis of EML4-ALK fusion genes and introduce the useful-
ness of long distance- (LD-) or long distance inverse-poly-
merase chain reaction (LDI-PCR) on solid tumors including 
lung cancer.
  As correctly mentioned by Jin et al. (1), the shortcomings of 
ALK breakapart FISH test include its inability to identify accu-
rate subtypes of the EML4-ALK fusion gene and discriminate 
the changes in ALK partner genes, which is due to the charac-
teristics of the breakapart FISH probe. To confirm the presence 
of a partner gene or the fusion gene subtype, additional meth-
ods such as PCR would be always necessary. In that sense, the 
fact that Jin et al. (1) used RT-PCR as a molecular screening meth-
od was a good approach to overcome the above mentioned lim-
itations of FISH. However, it should be noted that previous stud-
ies have indicated a number of variant EML4-ALK fusion gene 
subtypes which could be missed if not designing a complete set 
of multiplex oligonucleotides (7). This is one of the important 
limitations of RT-PCR in fusion gene analysis that Jin et al. (1) 
have overlooked. Furthermore, ALK gene has additional fusion 
partners such as TGF, KIF5B, and KLC1 in lung cancer (8). 
  We believe that the established methodologies concerning MLL 
rearrangements in leukemia patients could be a prototypic exam-
ple of similar technical pitfalls. As widely known, MLL rearrange-
ments have more than 70 partner genes while each MLL rear-
rangement can also show various types of fusion genes due to the 
involvement of different introns of the MLL- and the correspond-
ing partner gene (3). As mentioned in our recent paper, “Diagnos-
tic standardization of leukemia fusion gene detection system us-
ing multiplex reverse transcriptase-polymerase chain reaction in 
Korea,” (6) these characteristics limit a complete detection of all 
MLL rearrangements in any multiplex RT-PCR method that has 
been developed so far. This is also pertinent to the reason why 
FISH has been used as a screening method in various leukemia 
fusion gene analyses, despite its aforementioned limitations. More-
over, another important limitation of the RT-PCR method is that 
it uses RNA and a subsequent complementary DNA (cDNA) as 
clinical specimens that are relatively unstable (compared to ge-
nomic DNA). In fusion gene analyses on hematologic malignan-
cies, it is not uncommon to encounter such a situation where an 
alternative method is required because of the unstable nature of 
RNA samples as well as the unavailability of the sample in the first 
place. Recently, we also have been trying to resolve such limitations 
of FISH and RT-PCR methods in our molecular analyses on leu-
kemia patients that showed fusion genes other than MLL rear-
rangements by using a LD-/LDI-PCR method (9-11). 
  The principles of LD-/LDI-PCR were explained in our previous 
papers in detail (3, 4). To briefly elaborate, LD-/LDI-PCR is a fu-
sion breakpoint analysis method that uses stable genomic DNA 
and incorporates both the sensitivity of the FISH method that can 
screen all types of fusion genes and the specificity of the RT-PCR 
method that can confirm specific subtypes of a fusion gene. Fu-
sion gene analysis using such LD-/LDI-PCR method has not only 
been successfully implemented in the diagnostic schemes for leu-Correspondence: To the Editor
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kemia patients but has turned out to be informative also on solid 
tumors, like e.g. pilocytic astrocytoma or Lynch syndrome patients 
(5, 12, 13).
  Intron 19 of the ALK gene resembles the breakpoint cluster   
region and has a size of about 1,932 bp. Thus, the LD-/LDI-PCR 
seems to be a highly feasable method, as it is for MLL, PML-RARA 
or FGFR1 rearrangement analyses (3, 4, 9-11). LDI-PCR could be 
expected to be a powerful method to analyze all EML4-ALK vari-
ants and also any other ALK rearrangements having known or 
even unknown fusion partner genes (Fig. 1). Therefore, we be-
lieve that the implementation of such a novel technology for the 
molecular diagnoses of lung cancer patients would contribute to 
a more accurate identification of ALK fusion genes in NSCLC as 
well as to the molecular characterization of EML4-ALK fusion gene 
in Korean or other ethnic lung cancer patients that can be used 
as a more precise founding information for molecular targeted 
therapy. We hope this new LD-/LDI-PCR method can be used 
in a greater variety of molecular diagnosis of solid tumors in the 
near future. 
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Fig. 1. Schematic representation of long distance inverse-polymerase chain reaction 
(LDI-PCR) for analyzing ALK rearrangements. LDI-PCR can analyze any kind of EML4-
ALK fusion variant and other (or unknown) ALK partner genes. (A) One ALK wildtype 
allele and one rearranged ALK allele are presented. Genomic breakpoint cluster region 
(BCR) of ALK in non-small cell lung cancer (NSCLC) is located in 19th intron of ALK 
gene. (R: restriction enzyme) (B) General principle of LDI-PCR for the detection of ALK 
fusion gene analysis. Two asterisks show the derivative (target) bands by LDI-PCR in 
ALK fusion gene analysis. (C) Demonstration of known (EML4, TFG, KIF5B, KLC1) or 
unknown partner genes in ALK rearrangements. 
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